Skip to main content
Registration
Registration Information
Visa Support Letters
Meeting Information
Academic Showcase
Award Winners
Health & Safety at ICPE 2023
Hotel & Travel
FAQ
Accessibility
Sustainability
Conference Program
Full Schedule
Preconference Skills Courses
Presenter/Poster Information
Browse By Date
Tuesday, August 22, 2023
Wednesday, August 23, 2023
Thursday, August 24, 2023
Friday, August 25, 2023
Saturday, August 26, 2023
Sunday, August 27, 2023
Browse By Title
Browse By Speaker
Speaker Look-up
Posters
Spotlight Posters
Browse by Title
Browse by Author
Browse by Date
Tracks
Poster Gallery
Login Required
Exhibitors & Sponsors
Become an Exhibitor/Sponsor
Exhibitor/Sponsor Login
Find an Exhibitor/Sponsor
Browse by Company
Sponsor List
Evaluation
Login Required
Conference App
Toggle navigation
Login
Search
Home
Registration
Registration Information
Visa Support Letters
Meeting Information
Academic Showcase
Award Winners
Health & Safety at ICPE 2023
Hotel & Travel
FAQ
Accessibility
Sustainability
Conference Program
Full Schedule
Preconference Skills Courses
Presenter/Poster Information
Browse By Date
Tuesday, August 22, 2023
Wednesday, August 23, 2023
Thursday, August 24, 2023
Friday, August 25, 2023
Saturday, August 26, 2023
Sunday, August 27, 2023
Browse By Title
Browse By Speaker
Speaker Look-up
Posters
Spotlight Posters
Browse by Title
Browse by Author
Browse by Date
Tracks
Poster Gallery
Login Required
Exhibitors & Sponsors
Become an Exhibitor/Sponsor
Exhibitor/Sponsor Login
Find an Exhibitor/Sponsor
Browse by Company
Sponsor List
Evaluation
Login Required
Conference App
ICPE 2023 Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Poster Schedule
All Days
Fri, Aug 25
Sat, Aug 26
Sun, Aug 27
Poster Schedule
343 results found
Type here to filter the list
Sunday, August 27, 2023
8:00 AM – 1:30 PM
ADT
(001) Evaluation Of The Potential Rebound Effect Of Denosumab Discontinuation: A Comparative Study Of Five Different Types Of Antiosteoporotic Medications
Favorite
8:00 AM – 1:30 PM
ADT
(002) Challenges and future perspectives of enhanced passive safety surveillance (EPSS) of influenza vaccines in Europe
Favorite
8:00 AM – 1:30 PM
ADT
(003) Clinical Harms Associated with Xylazine Use in Humans
Favorite
8:00 AM – 1:30 PM
ADT
(004) Mapping the Information Pathways of Adverse Reactions Through Clinical Event Sequences, Patient Interactions with the Healthcare System and Generation of Different Data Streams – a Qualitative Pilot Study
Favorite
8:00 AM – 1:30 PM
ADT
(005) A Real-world Evidence on Electrolyte Disorders with Piperacillin/Tazobactams :Using the FARES Database over 10 years
Favorite
8:00 AM – 1:30 PM
ADT
(006) Trends and Patterns of the Reported Antimicrobial Errors to the Eastern Region’s Medical Centers in Saudi Arabia: A Cross-Sectional Study
Favorite
8:00 AM – 1:30 PM
ADT
(007) Characterization of Japanese Risk Management Plans Using Automatically Extracted Information by Robotic Process Automation Tool
Favorite
8:00 AM – 1:30 PM
ADT
(008) Hypersensitivity Reactions with Ultrasound Contrast Agents in Patients with a History of Polyethylene Glycol Allergy
Favorite
8:00 AM – 1:30 PM
ADT
(009) Pharmacovigilance of pharmaceutical products in colorectal cancer: a systematic review and metanalysis
Favorite
8:00 AM – 1:30 PM
ADT
(010) Comparing the Efficacy and Safety of Dolutegravir and Efavirenz-based Antiretroviral Regimens: A Retrospective Study
Favorite
8:00 AM – 1:30 PM
ADT
(011) Trimethoprim-Sulfamethoxazole-associated early neutropenia in Mexican adults living with HIV: a cohort study
Favorite
8:00 AM – 1:30 PM
ADT
(012) Safety of using nirmatrelvir/ritonavir and cardiovascular medications with potential drug-drug interactions: Comparative safety analysis using WHO international database
Favorite
8:00 AM – 1:30 PM
ADT
(013) Risk of gastrointestinal bleeding associated with antiviral treatment among influenza patients
Favorite
8:00 AM – 1:30 PM
ADT
(014) Association between use of fluoroquinolones and risk of mitral or aortic valve regurgitation: a population-based cohort study
Favorite
8:00 AM – 1:30 PM
ADT
(015) In-utero azathioprine exposure and neurodevelopmental disorders in the offspring
Favorite
8:00 AM – 1:30 PM
ADT
(016) Cardiovascular Adverse Events associated with JAK Inhibitor versus TNF Inhibitor: A Disproportionality Analysis in National Pharmacovigilance Database of Korea
Favorite
8:00 AM – 1:30 PM
ADT
(017) Cohort Study of Serious Angioedema in Association with Sacubitril/Valsartan Use in Black Patients with Heart Failure
Favorite
8:00 AM – 1:30 PM
ADT
(018) Interaction Between Cannabis And Cytochromes P450 Substrates: Potential Safety Signals from a Disproportionality Analysis Using the US Food And Drug Administration Adverse Event Reporting System Database
Favorite
8:00 AM – 1:30 PM
ADT
(019) A new tool to estimate comorbidities at the population-level in the United States
Favorite
8:00 AM – 1:30 PM
ADT
(020) Association between Cumulative Corticosteroid Dose and Risk of Avascular Necrosis in patients with Systemic Lupus Erythematosus : A nested case-control study
Favorite
8:00 AM – 1:30 PM
ADT
(021) Aspirin and non-aspirin antiplatelet agents use and risk of ischemic and hemorrhagic stroke in patients with non-valvular atrial fibrillation with and without anticoagulant therapy: a case-referent study
Favorite
8:00 AM – 1:30 PM
ADT
(022) Temporal Trends in Adverse Drug Reactions Reports of Medicines for Treating Human Immunodeficiency Virus and Tuberculosis, and All Diseases: Joinpoint Regression
Favorite
8:00 AM – 1:30 PM
ADT
(023) The Impact of the Removal of Liver Injury Warning and Liver Testing Requirement on Ambrisentan Use and Liver Function Testing
Favorite
8:00 AM – 1:30 PM
ADT
(025) Expanding Capabilities for Unapproved Cannabis-Derived Product Surveillance in the United States, TriNetX, July 1, 2018 – June 30, 2022
Favorite
8:00 AM – 1:30 PM
ADT
(026) Adverse Drug Reaction Reporting Among Nurses in Nigeria: Opinion Survey of Their Knowledge, Attitude, and Practice
Favorite
8:00 AM – 1:30 PM
ADT
(027) Factors linked to hospital-admission of chronic non-cancer pain patients prescribed long-term strong opioids
Favorite
8:00 AM – 1:30 PM
ADT
(028) Development and Implementation of the National Clozapine Safety System for the Department of Veterans Affairs
Favorite
8:00 AM – 1:30 PM
ADT
(029) Characterizing of adverse events across 30,000 peer reviewed case report publications
Favorite
8:00 AM – 1:30 PM
ADT
(030) Development and validation of technology assisted tool for Data mining of public version of FAERS database using python language
Favorite
8:00 AM – 1:30 PM
ADT
(031) Medical Scandal with illegally diluted Chemotherapy in Germany: Prognosis of Patients with Breast and non-solid Cancers
Favorite
8:00 AM – 1:30 PM
ADT
(032) Exploring the Use of Electronic Health Records (EHR) Data for Active Safety Surveillance of Epidiolex in PCORnet, July 1, 2018- July 1, 2022
Favorite
8:00 AM – 1:30 PM
ADT
(033) Prescription Sequence Symmetry Analysis of Administrative Claims Data for Detection of Opioid Use Adverse Events
Favorite
8:00 AM – 1:30 PM
ADT
(034) Relationship Between Misuse of Substances and Abuse as Reported in the FDA FAERS data
Favorite
8:00 AM – 1:30 PM
ADT
(035) Medication Safety Stewardship in Antibiotic usage in Critical Care Units
Favorite
8:00 AM – 1:30 PM
ADT
(036) Physician Perceptions of and Experiences with Risk Evaluation and Mitigation Strategies: Results from a National Survey
Favorite
8:00 AM – 1:30 PM
ADT
(037) Is aggregate use of published case reports as a viable option for augmenting pharmacovigilance? An applied example of pembrolizumab-related adverse events in non-small cell lung cancer patients receiving first-line treatment
Favorite
8:00 AM – 1:30 PM
ADT
(038) Risk of Cholelithiasis and Cholecystitis for antidiabetic medications: Evidence synthesis from a disproportionality analysis
Favorite
8:00 AM – 1:30 PM
ADT
(039) RAAS Inhibitors-Related Adverse Drug Reactions and the Risk of Subsequent Cardiovascular Event and All-Cause Mortality: A Cohort Study in UK Primary Care
Favorite
8:00 AM – 1:30 PM
ADT
(040) Bleeding related adverse events associated with antiviral treatment in influenza patients: a disproportionality analysis using FDA adverse event reporting system (FAERS)
Favorite
8:00 AM – 1:30 PM
ADT
(041) Budsinfo: A User-Friendly Platform for Reporting the Effects of Cannabis and Hemp-Derived Products
Favorite
8:00 AM – 1:30 PM
ADT
(042) Laboratory screening tests before and during the use of systemic immunomodulatory agents in patients with chronic inflammatory skin diseases
Favorite
8:00 AM – 1:30 PM
ADT
(043) Health Canada’s Vigilance Framework for Cannabis: A summary of adverse reactions associated with cannabis products
Favorite
8:00 AM – 1:30 PM
ADT
(044) Open insurance claims database vs closed insurance claims database to support pharmacovigilance review of potential safety event in patients with B-cell malignancies: a fit for purpose evaluation
Favorite
8:00 AM – 1:30 PM
ADT
(045) Impact of European Union label changes to avoid inadvertent use of once-weekly methotrexate: A cross-sectional survey amongst prescribers, pharmacists and patients on awareness, knowledge, and behaviour
Favorite
8:00 AM – 1:30 PM
ADT
(046) Extent of apremilast exposure misclassification in CPRD Aurum: a validation study
Favorite
8:00 AM – 1:30 PM
ADT
(047) Technology Aided Intervention to Improve the Metabolic Monitoring Rate in Patients on Atypical Antipsychotics
Favorite
8:00 AM – 1:30 PM
ADT
(048) Quality compliance while conducting NIS studies: critical success factors assessment and the use of key performance indicators
Favorite
8:00 AM – 1:30 PM
ADT
(049) Poisonings with Antidepressants in Relation to Prescriptions; Venlafaxine and Amitriptyline Stands Out
Favorite
8:00 AM – 1:30 PM
ADT
(050) A Qualitative Approach in Assessing the Contributing Factors towards the Medication Error-Prone Behavior amongst the Healthcare Professionals
Favorite
8:00 AM – 1:30 PM
ADT
(051) Monitoring of adverse events during seasonal malaria chemoprevention campaigns in children aged 3-59 months in Burkina Faso: A real-world evidence
Favorite
8:00 AM – 1:30 PM
ADT
(052) Initiation and Implementation of a Medication Error Reporting and Monitoring Program: A Developing Country Scenario
Favorite
8:00 AM – 1:30 PM
ADT
(053) Proton pump inhibitors and risk of kidney diseases: An overview of meta-analyses
Favorite
8:00 AM – 1:30 PM
ADT
(054) Supporting pharmacovigilance signal validation and prioritisation with analyses of routinely collected health data – lessons learned from an EHDEN network study
Favorite
8:00 AM – 1:30 PM
ADT
(055) Psychological and Neurological Adverse Drug Events Associated with Direct Acting Antivirals Agents Used for Hepatitis C Virus: Analysis and Comparison of the FDA Adverse Event Reporting System (FAERS) and Lexicomp
Favorite
8:00 AM – 1:30 PM
ADT
(056) A Novice Stratagem in the Quantification of the Contributing Factors Associated to Medication Errors
Favorite
8:00 AM – 1:30 PM
ADT
(058) Impact of Educational Awareness on Knowledge and Attitude of ADR Reporting Among Medical, Pharmacy, Dentistry and Nursing Students: An Interventional Study
Favorite
8:00 AM – 1:30 PM
ADT
(059) Classifying Chemotherapy Chaos: Navigating Blood & Lymphatic Side Effects
Favorite
8:00 AM – 1:30 PM
ADT
(060) Rapid Use of Real-World Data in Safety Signal Assessment
Favorite
8:00 AM – 1:30 PM
ADT
(062) Fatal tramadol intoxications in Sweden, almost 50% of the individuals lacked a prescription
Favorite
8:00 AM – 1:30 PM
ADT
(063) Causality assessment of adverse drug reactions in post-authorization settings: An analysis from four different countries to find out the most comprehensive and easy-to-use tool
Favorite
8:00 AM – 1:30 PM
ADT
(064) Capecitabine-Induced Adverse Reactions in Patients with Biliary Tract Cancer: Evidence from Spontaneous Reporting Data Analysis and Systematic Review & Meta-Analysis
Favorite
8:00 AM – 1:30 PM
ADT
(065) Potential Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions(DDIs) of QT Prolonging Drugs in a cohort of Psychiatry Patients
Favorite
8:00 AM – 1:30 PM
ADT
(067) Uncovering the Skin Reactions: Retrospectively Analyzing the Adverse Drug Reactions Related to Skin & Subcutaneous Tissues disorders
Favorite
8:00 AM – 1:30 PM
ADT
(068) Descriptive Analysis of Safety of Ketamine Utilizing FDA Adverse Events Reporting System FAERS Database
Favorite
8:00 AM – 1:30 PM
ADT
(069) Sociodemographic Factors Affecting Drug Interactions in Stable Angina Pectoris Patients in the Cardiology Polyclinic of A Tertiary General Hospital in Banjarmasin
Favorite
8:00 AM – 1:30 PM
ADT
(070) Application of machine learning methods in risk assessment of fracture associated with antihypertensives in older people with a large number of confounders
Favorite
8:00 AM – 1:30 PM
ADT
(071) Drug Plan Monitoring of Paxlovid Adherence and Patient-Reported Adverse Events in British Columbia
Favorite
8:00 AM – 1:30 PM
ADT
(072) Association between Mortality and Cumulative Exposure to Antipsychotics, Antidepressants and Benzodiazepines in Patients with Schizophrenia: A Real-World Observational Study
Favorite
8:00 AM – 1:30 PM
ADT
(073) Purine antimetabolites associated pneumocystis jiroveci pneumonia among autoimmune and cancer population
Favorite
8:00 AM – 1:30 PM
ADT
(074) Active and Passive Safety Surveillance in Children Receiving Live Attenuated Influenza Vaccine (LAIV), in England During Early Influenza Seasons from 2014/2015 to 2021/2022
Favorite
8:00 AM – 1:30 PM
ADT
(075) Reasons for Treatment Alteration in Dermatology Patients: Insights from Unstructured Clinical Notes
Favorite
8:00 AM – 1:30 PM
ADT
(076) Drug Repurposing for Hepatocellular Carcinoma via Real World Data Corroborated with Bioinformatics
Favorite
8:00 AM – 1:30 PM
ADT
(077) A Canadian Approach to Classifying Acute Kidney Injury and Other Reports of Renal Adverse Events of Interest Following Immunization
Favorite
8:00 AM – 1:30 PM
ADT
(078) Perception of Facilitators and Barriers to Strengthen restriction of non-medical use opioid prescription among healthcare practitioner in China: a qualitative study
Favorite
8:00 AM – 1:30 PM
ADT
(079) Graph Machine Learning in Adverse Events Safety Signal Management: A Research Proposal
Favorite
8:00 AM – 1:30 PM
ADT
(080) Identification of a novel signal congenital scoliosis for zopiclone through FDA FAERS database
Favorite
8:00 AM – 1:30 PM
ADT
(081) Active surveillance and evaluation of anosmia/ageusia following mRNA-1273 administration: Learnings from a US administrative claims database study
Favorite
8:00 AM – 1:30 PM
ADT
(083) Treatment Patterns Before, During, and After Pregnancy in Inflammatory Bowel Disease
Favorite
8:00 AM – 1:30 PM
ADT
(084) Patterns of antiseizure medications prescriptions among pregnant people with epilepsy: a utilization study in three Canadian provinces
Favorite
8:00 AM – 1:30 PM
ADT
(085) Trends and patterns of antiseizure medication prescribing during pregnancy between 1995 and 2018 in the United Kingdom
Favorite
8:00 AM – 1:30 PM
ADT
(086) Trends in the Use of Prescription Medications Among Women of Reproductive Age by Pregnancy Status in the U.S., 2009-2020
Favorite
8:00 AM – 1:30 PM
ADT
(087) Characteristics and Outcomes of Pregnant Patients and Their Infants in a Linked Maternal-Infant Administrative Claims Database
Favorite
8:00 AM – 1:30 PM
ADT
(088) Changes in Diclectin Utilization Trends in Ontario Following Media Attention: A Time-Series Analysis
Favorite
8:00 AM – 1:30 PM
ADT
(089) Application of a Structured Process to Identify Fit-for-Purpose Data for Pregnancy Database Study
Favorite
8:00 AM – 1:30 PM
ADT
(090) Use of Medication for Gastroesophageal Reflux During Pregnancy and Adverse Birth Outcomes
Favorite
8:00 AM – 1:30 PM
ADT
(091) Abortion-related Trends Before and After the Dobbs Decision within TriNetX Electronic Medical Record Data
Favorite
8:00 AM – 1:30 PM
ADT
(092) Trends in Medically Assisted Reproduction Utilization and Obstetrical as well as Perinatal Outcomes in Quebec between 2005 and 2015 - the Impact of the Universal Access Program: an interrupted time series analysis
Favorite
8:00 AM – 1:30 PM
ADT
(093) Expanding Pregnancy Surveillance Programs to Assess Effects of Medicinal Product Exposure During Lactation
Favorite
8:00 AM – 1:30 PM
ADT
(094) A first step in drug utilisation and safety studies: identifying indications for drug use in administrative data sources. A pilot study with gabapentinoids in a French healthcare data source. A contribution from the ConcePTION project
Favorite
8:00 AM – 1:30 PM
ADT
(095) Utilization of prescribed drugs in pregnancy between 2015 and 2021 in Switzerland: A retrospective analysis of Swiss healthcare claims data
Favorite
8:00 AM – 1:30 PM
ADT
(096) Medications considered to have substantial teratogenic risk commonly used in US pregnant population – quality of evidence and magnitude of risk
Favorite
8:00 AM – 1:30 PM
ADT
(097) Lactation Studies: When are healthy volunteers an option?
Favorite
8:00 AM – 1:30 PM
ADT
(098) Exposure to teratogens in pregnancy and in women of childbearing age between 2015 and 2021 in Switzerland: A retrospective analysis of Swiss healthcare claims data
Favorite
8:00 AM – 1:30 PM
ADT
(099) Patterns of prescription medication use during pregnancy in the United States, 1997–2018
Favorite
8:00 AM – 1:30 PM
ADT
(100) A Systematic Review of Secondary Databases Used in Paternal Drug Exposure Studies and Discussion of Paternal Exposure Related Pregnancy Outcomes
Favorite
8:00 AM – 1:30 PM
ADT
(101) Drug utilisation studies in pregnant women for newly licensed medicinal products: reflections from IMI-ConcePTION
Favorite
8:00 AM – 1:30 PM
ADT
(102) Development of Drug Trees to Support TreeScan Analyses of Prenatal Drug Exposures Associated with Fetal Cardiac Malformations
Favorite
8:00 AM – 1:30 PM
ADT
(103) Identification of Pregnancies Without a Recorded Outcome in German Claims Data
Favorite
8:00 AM – 1:30 PM
ADT
(104) Antiseizure medication use in pregnancy and adverse neonatal birth outcomes: a population-based cohort study
Favorite
8:00 AM – 1:30 PM
ADT
(105) Real-world prenatal exposure to topiramate among women of childbearing age and their contraceptive use in the USA
Favorite
8:00 AM – 1:30 PM
ADT
(106) Safety and Effectiveness of Insulin Aspart versus Other Bolus Insulins in Women with Pre-existing Type 1 Diabetes During Pregnancy
Favorite
8:00 AM – 1:30 PM
ADT
(107) The AMerican PREGNANcy-Mother-Child Cohort (AM-PREGNANT): Description and prevalence of main perinatal outcomes and medication use
Favorite
8:00 AM – 1:30 PM
ADT
(108) ADHD and induced abortion in young women: a population-based study from Norway
Favorite
8:00 AM – 1:30 PM
ADT
(109) Comparing prevalence of neural tube defects and orofacial clefts in Global Burden of Disease study and EUROCAT registry data
Favorite
8:00 AM – 1:30 PM
ADT
(110) Determinants of Participation in Clinical Trials During Pregnancy and Lactation
Favorite
8:00 AM – 1:30 PM
ADT
(111) Patterns of Antibiotic Utilization for Urinary Tract Infection During Pregnancy, 2007-2020
Favorite
8:00 AM – 1:30 PM
ADT
(112) Gabapentin use during pregnancy and adverse neonatal birth outcomes: a population-based cohort study
Favorite
8:00 AM – 1:30 PM
ADT
(113) Review of Mother-Infant Linkage Algorithms in Health Care Databases
Favorite
8:00 AM – 1:30 PM
ADT
(114) A Comparison of Postpartum Opioid Consumption and Opioid Discharge Prescriptions Among Opioid Naïve Patients and Those With Opioid Use Disorder
Favorite
8:00 AM – 1:30 PM
ADT
(115) Associations between Antibiotics and Non-Cardiac Birth Defects, National Birth Defects Prevention Study and Birth Defects Study to Evaluate Pregnancy Exposures
Favorite
8:00 AM – 1:30 PM
ADT
(116) Antibiotic exposure during pregnancy: prevalence and associated factors in a French population-based study (2010-2019)
Favorite
8:00 AM – 1:30 PM
ADT
(117) Time Trends of HIV Treatment in Girls and Women of Childbearing Age in Germany
Favorite
8:00 AM – 1:30 PM
ADT
(118) School readiness among children exposed to opioids during pregnancy in Manitoba, Canada
Favorite
8:00 AM – 1:30 PM
ADT
(119) Factors Associated with Health Plan Disenrollment During Pregnancy Among US Commercially Insured Women
Favorite
8:00 AM – 1:30 PM
ADT
(120) Maternal acetaminophen intake in pregnancy and the risk of childhood cancer
Favorite
8:00 AM – 1:30 PM
ADT
(121) Pregnancy and Fetal Outcomes Following Paternal Exposure to Glatiramer Acetate
Favorite
8:00 AM – 1:30 PM
ADT
(122) Antidepressant Use During Trimester One And Pregnancy Loss: A Causal Analysis In The UK CPRD
Favorite
8:00 AM – 1:30 PM
ADT
(123) Pregnancy and Fetal Outcomes Following Maternal Exposure to Glatiramer Acetate in 3 Trimesters of Pregnancy
Favorite
8:00 AM – 1:30 PM
ADT
(124) Use of multiple sclerosis disease-modifying therapies during pregnancy in France from 2010 to 2021
Favorite
8:00 AM – 1:30 PM
ADT
(125) Pregnancy Rates in Patients with Immune-mediated Inflammatory Diseases
Favorite
8:00 AM – 1:30 PM
ADT
(126) Long-Term Outcomes of Children exposed to RAAS-Inhibitors During Pregnancy
Favorite
8:00 AM – 1:30 PM
ADT
(127) Antidepressant and Psychotherapy Initiation Among Patients with New Episodes of Depression During Pregnancy
Favorite
8:00 AM – 1:30 PM
ADT
(128) Clinical Quality of Information of Primary Pregnancy Pharmacovigilance Data Sources – A ConcePTION Project
Favorite
8:00 AM – 1:30 PM
ADT
(129) Benefit-Risk Assessment Conceptual Framework for Exposure to Biologics during Pregnancy
Favorite
8:00 AM – 1:30 PM
ADT
(130) Lactation Studies of Biologics and Design Challenges
Favorite
8:00 AM – 1:30 PM
ADT
(131) Database profile: EPI-MERES, a nationwide mother-child register built from the French National Health Data System (SNDS) for pregnancy and paediatric pharmacoepidemiological research
Favorite
8:00 AM – 1:30 PM
ADT
(132) Using a causal framework and electronic health record data to infer the effects of antidepressant exposure in pregnancy
Favorite
8:00 AM – 1:30 PM
ADT
(133) Assessment of maternal acetaminophen use during pregnancy: a comparison of self-reported intake with maternal and newborn biomarker measures
Favorite
8:00 AM – 1:30 PM
ADT
(134) Core Evidence Elements for generating medicine safety evidence for pregnancy using population-based data: Recommendations from IMI-ConcePTION
Favorite
8:00 AM – 1:30 PM
ADT
(135) Congenital Heart Defects Among Infants Linked To Mothers In The Healthcore Integrated Research Database
Favorite
8:00 AM – 1:30 PM
ADT
(136) Specifying and mapping design choices from the protocol to the study script in a complex multi-database study to improve transparency and efficiency: the experience of a demonstration project in IMI-ConcePTION
Favorite
8:00 AM – 1:30 PM
ADT
(137) The Impact of Psychiatric Diseases and Antiepileptic Drugs Use in Pregnant Women with Epilepsy in Asia Population
Favorite
8:00 AM – 1:30 PM
ADT
(138) Monitoring pregnancies exposed to galcanezumab for migraine in a United States (US) administrative claims database
Favorite
8:00 AM – 1:30 PM
ADT
(139) Challenges and opportunities of European population-based data sources to support regulatory safety-related research questions in pregnancy
Favorite
8:00 AM – 1:30 PM
ADT
(140) Disruptions In Prenatal Care Visits During The Pandemic: A Population-Based Cohort Study in Manitoba, Canada
Favorite
8:00 AM – 1:30 PM
ADT
(141) Paxlovid Prophylaxis or Treatment in Pregnancy: Data from the Organization of Teratology Information Specialists (OTIS) Pregnancy Registry
Favorite
8:00 AM – 1:30 PM
ADT
(142) Health Literacy and Medication Adherence in Hypertensive Pregnant and Postpartum Patients: A Cross-sectional study
Favorite
8:00 AM – 1:30 PM
ADT
(143) A first step to study the use and safety of multiple sclerosis (MS) drugs during pregnancy: identifying cases of MS and assessing MS prevalence. A pilot study in a French health care datasource. A contribution from the ConcePTION project
Favorite
8:00 AM – 1:30 PM
ADT
(144) Antiseizure medication safety in pregnant people for non-epilepsy conditions
Favorite
8:00 AM – 1:30 PM
ADT
(145) Ponesimod Pregnancy Outcomes Enhanced Monitoring (POEM) Program to Evaluate Reproductive and Embryofetal Toxicity
Favorite
8:00 AM – 1:30 PM
ADT
(146) Prevalence of multiple sclerosis in women of childbearing age potential in Europe: A contribution from IMI ConCEPTION
Favorite
8:00 AM – 1:30 PM
ADT
(147) Association between non-steroid anti-inflammatory drugs use during pregnancy and premature birth in the NISAMI cohort
Favorite
8:00 AM – 1:30 PM
ADT
(148) Assesing the Safety of Antihypertensive medication in Pregnancy (ASAP project)
Favorite
8:00 AM – 1:30 PM
ADT
(149) First trimester exposure to smoking cessation pharmacotherapies and the risk of major congenital malformations: A multi-national cohort study
Favorite
8:00 AM – 1:30 PM
ADT
(150) Risk of Major Congenital Malformations Associated with Topical Retinoid Use in Pregnancy – Results From Nordic Population-Based Cohorts
Favorite
8:00 AM – 1:30 PM
ADT
(151) A Safety Comparison of Continuing Versus Discontinuing Triptans for Acute Migraine Treatment in Early Pregnancy
Favorite
8:00 AM – 1:30 PM
ADT
(152) To whom results apply? Assessing the impact of extended continuous enrollment inclusion criteria in pharmacoepidemiologic studies of medication use in pregnancy
Favorite
8:00 AM – 1:30 PM
ADT
(153) Patterns Of Antidepressant Prescribing During Pregnancy Between 1996 And 2018 Using The Clinical Practice Research Datalink
Favorite
8:00 AM – 1:30 PM
ADT
(154) Maternal mental health during the COVID-19 pandemic and its impact on child cognitive development
Favorite
8:00 AM – 1:30 PM
ADT
(155) Maternal Use of Benzodiazepines and Risk of Spontaneous Abortion: A Nationwide Case-Time Control Study
Favorite
8:00 AM – 1:30 PM
ADT
(156) The Impact of Nicotine Replacement Therapy on Maternal-Neonatal Outcomes and Smoking Cessation in Pregnant Women: A Systematic Review and Meta-Analysis
Favorite
8:00 AM – 1:30 PM
ADT
(157) Childhood cerebral adrenoleukodystrophy (CCALD) in France: epidemiology, natural history, and burden – a real-world study using registry data linked to the French national claims database
Favorite
8:00 AM – 1:30 PM
ADT
(158) Healthcare Resource Utilization from OPERA: A Real-World Study of Pegcetacoplan Treatment in US Adults with Paroxysmal Nocturnal Hemoglobinuria
Favorite
8:00 AM – 1:30 PM
ADT
(159) Prevalence and use of medications for autoimmune diseases during pregnancy
Favorite
8:00 AM – 1:30 PM
ADT
(160) Metabolic Decompensation Events in the Propionic Acidemia Population within a Large EHR-Based Real-World Data Source
Favorite
8:00 AM – 1:30 PM
ADT
(161) Impact of population opt-outs on rare disease prevalence: a simulation study
Favorite
8:00 AM – 1:30 PM
ADT
(162) Rare disease observational research enabled through the federated data network approach: PHederation use case
Favorite
8:00 AM – 1:30 PM
ADT
(163) A Novel Patient-Centered Real-World Evidence Study Designed to Better Understand Short Bowel Syndrome Using Longitudinal Data in the United States
Favorite
8:00 AM – 1:30 PM
ADT
(164) Methodological Approaches for External Control Arms in Rare Diseases
Favorite
8:00 AM – 1:30 PM
ADT
(165) Improving Longitudinally in Rare Disease Data Capture in Real-world Evidence Combining Clinical Trials and Observational Data: A Case Study Using EVOLVE
Favorite
8:00 AM – 1:30 PM
ADT
(166) Novel methods for the identification of a rare disease, hemophagocytic lymphohistiocytosis (HLH)
Favorite
8:00 AM – 1:30 PM
ADT
(167) Drug use in presence of contraindications in MG patients in three Italian Regions: a real-world observational study in Italy - The CAESAR study
Favorite
8:00 AM – 1:30 PM
ADT
(168) Emicizumab wastage estimation for treating people with hemophilia A and inhibitors who failed immune tolerance induction according to the current Brazilian public health protocol
Favorite
8:00 AM – 1:30 PM
ADT
(170) Prevalence and Incidence of Multiple System Atrophy in Real World Setting: Results from US Claims Database
Favorite
8:00 AM – 1:30 PM
ADT
(171) Clinical Outcomes and Population Characteristics in Fibrodysplasia Ossificans Progressiva: A Systematic Literature Review
Favorite
8:00 AM – 1:30 PM
ADT
(172) A Feasibility Evaluation of US Healthcare Claims Data to Describe Patient Healthcare Utilization Patterns for Dengue Infection
Favorite
8:00 AM – 1:30 PM
ADT
(173) Descriptive Epidemiology of Adult T-cell Leukemia/Lymphoma in the United States
Favorite
8:00 AM – 1:30 PM
ADT
(174) An expanded algorithm to estimate prevalence of amyotrophic lateral sclerosis in US claims and UK primary care
Favorite
8:00 AM – 1:30 PM
ADT
(175) Hereditary angioedema case validation using medical claims data from commercially insured patients
Favorite
8:00 AM – 1:30 PM
ADT
(176) Epidemiology and Acute Care Utilization of Patients with Sickle Cell Disease who Present to the Emergency Department
Favorite
8:00 AM – 1:30 PM
ADT
(177) Clinical Characteristics of the Propionic Acidemia Population Identified Within a Large EHR-Based Real-World Data Source (2015-2022)
Favorite
8:00 AM – 1:30 PM
ADT
(178) Real world evidence in Rare Disease – Application of fit for purpose data sources framework in portopulmonary hypertension
Favorite
8:00 AM – 1:30 PM
ADT
(179) Characterizing Patient Care Before And After A Myasthenia Gravis Diagnosis
Favorite
8:00 AM – 1:30 PM
ADT
(181) Descriptive Epidemiology of Peripheral T-Cell Lymphoma in the United States
Favorite
8:00 AM – 1:30 PM
ADT
(182) Alternative Analytic Approaches to Forming a Benchmark Cohort in Rare Diseases
Favorite
8:00 AM – 1:30 PM
ADT
(183) To Estimate the Frequency of Brain Metastases, Presentation of Metastases, Location, Treatment Pattern and paradigm changes in the Brain Metastases Management Among the Population of Southern Asia
Favorite
8:00 AM – 1:30 PM
ADT
(184) Challenges and Mitigations of Conducting a Long-Term Effectiveness Study in a Rare Disease (Spinal Muscular Atrophy)
Favorite
8:00 AM – 1:30 PM
ADT
(185) Descriptive Characteristics and Validation of Fibrotic Interstitial Lung Disease Patients (ILD) with and without progression Using a Claims Based Algorithm
Favorite
8:00 AM – 1:30 PM
ADT
(186) Appropriate Use of Observed Versus Expected Analyses for Newly Emerging Safety Concerns: The Case of Vaccine-Induced Thrombotic Thrombocytopenia Following COVID-19 Vaccination
Favorite
8:00 AM – 1:30 PM
ADT
(187) Prevalence of rare blood cancers in Europe: a population-based network cohort study part of DARWIN EU®
Favorite
8:00 AM – 1:30 PM
ADT
(188) Nationwide trends in hospitalization, medical costs, and mortality for asthma after introduction of biologics: a cross-sectional study in the United States
Favorite
8:00 AM – 1:30 PM
ADT
(189) Development and validation of a claims-based definitional algorithm for moderate asthma exacerbations
Favorite
8:00 AM – 1:30 PM
ADT
(190) Medicare Will Negotiate the Prices of Ten Prescription Drugs in 2026: Characteristics of Medicare Beneficiaries Using These Drugs
Favorite
8:00 AM – 1:30 PM
ADT
(191) Respiratory Syncytial Virus (RSV) and Bronchiolitis Epidemiology Among the United States Infant Medicaid Populations in Seven States
Favorite
8:00 AM – 1:30 PM
ADT
(192) The Burden of RSV and Bronchiolitis in the US Infant Medicaid Population Extends Beyond the Inpatient Setting
Favorite
8:00 AM – 1:30 PM
ADT
(193) Healthcare Burden Associated with Atrial Flutter: Analysis of a Nationally Representative, Commercial Claims Database in the United States
Favorite
8:00 AM – 1:30 PM
ADT
(194) Incidence of Autoimmune Diseases among Patients with Asthma in the US
Favorite
8:00 AM – 1:30 PM
ADT
(195) The TAK-medoids, an algorithm to visualize healthcare pathway pattern on a very large cohort of patients: application on 50 000 French patients with COPD
Favorite
8:00 AM – 1:30 PM
ADT
(196) Epidemiology of Injuries among National Basketball Association Players: 2013-14 through 2018-19
Favorite
8:00 AM – 1:30 PM
ADT
(197) Using Real-World Data to Evaluate Comparative Effectiveness Cohorts of Azithromycin Relative to Roflumilast in Individuals with Uncontrolled Chronic Obstructive Pulmonary Disease
Favorite
8:00 AM – 1:30 PM
ADT
(198) Qualitative Assessment on Access to Treatment and Perceived Challenges Among Asthma Patients in a Hill Village of Nepal
Favorite
8:00 AM – 1:30 PM
ADT
(200) Describing clinical outcomes in adults hospitalized with viral lung infections using US real-world data
Favorite
8:00 AM – 1:30 PM
ADT
(201) Real-World Data of Lung Cancer: What About Safety?
Favorite
8:00 AM – 1:30 PM
ADT
(202) BNT162b2 effectiveness after extending the primary-series dosing interval in children and adolescents
Favorite
8:00 AM – 1:30 PM
ADT
(203) Incidence of intussusception among children under 6 years of age in Ningbo, China, 2015-2021: a retrospective cohort study using electronic health records
Favorite
8:00 AM – 1:30 PM
ADT
(204) Predicting Drug Consumption in Relation to Respiratory Diseases: An Analysis of the National Organisation for the Provision of Health Services ( EOPYY) Dataset in Greece
Favorite
8:00 AM – 1:30 PM
ADT
(205) Efficacy and safety of different regimens in the treatment of patients with latent tuberculosis infection: A systematic review and network meta-analysis of randomized controlled trials
Favorite
8:00 AM – 1:30 PM
ADT
(206) Prevalence of Polypharmacy and Hyperpolypharmacy in Patients with Intellectual Disabilities: A Meta-Analysis
Favorite
8:00 AM – 1:30 PM
ADT
(207) Value of Serum Procalcitonin in Guiding Anti-infective Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Meta-analysis and Systematic Review
Favorite
8:00 AM – 1:30 PM
ADT
(208) Misclassification of Metformin and Insulin Exposure Among Individuals with Type 2 Diabetes Using Integrated Electronic Health Record and Pharmacy Claims Data
Favorite
8:00 AM – 1:30 PM
ADT
(209) Optimization-based Stable Balancing Weights vs. Propensity Score Weighting for Samples with High Covariate Imbalance
Favorite
8:00 AM – 1:30 PM
ADT
(210) Validation of alopecia coding in US claims data among women of childbearing age
Favorite
8:00 AM – 1:30 PM
ADT
(211) Machine Learning Based Prediction of Serious Adverse Events in Metastatic Breast Cancer Patients Receiving Zoledronic Acid
Favorite
8:00 AM – 1:30 PM
ADT
(212) Personalized Prescribing Portraits and Evidence Summaries on First-line Antihypertensive Prescribing: A Factorial Randomized Trial of Audit-and-Feedback
Favorite
8:00 AM – 1:30 PM
ADT
(213) Variable Selection for Transporting Estimates to Specific Target Populations
Favorite
8:00 AM – 1:30 PM
ADT
(214) Validation of Indication for Use (INDO) in the Danish National Prescription Registry
Favorite
8:00 AM – 1:30 PM
ADT
(215) Anticholinergic medication used and the risk of delirium in people with dementia- A self-controlled case series study
Favorite
8:00 AM – 1:30 PM
ADT
(216) Comparative safety of baricitinib versus TNFi in Rheumatoid Arthritis management in the French population: a propensity score-matched cohort study
Favorite
8:00 AM – 1:30 PM
ADT
(217) Risk Assessment of Hypocalcaemia in Patients with Renal Impairment Prescribed Bisphosphonate Preparations Using the MID-NET® in Japan
Favorite
8:00 AM – 1:30 PM
ADT
(218) Validity of an ICD-10 Algorithm for Nonfatal Myocardial Infarction Among US Medicare Older Adults
Favorite
8:00 AM – 1:30 PM
ADT
(219) Cardiovascular Risk Among Benign Prostatic Hyperplasia Patients Receiving Alpha Blockers and 5-Alpha Reductase Inhibitors
Favorite
8:00 AM – 1:30 PM
ADT
(220) Compliance of oral isotretinoin use with prescription and delivery guidelines between 2014 and 2021 in France
Favorite
8:00 AM – 1:30 PM
ADT
(222) Defining Provider Prescribing Preference as an Instrumental Variable: A Case Study of NOACs in Stroke Prevention
Favorite
8:00 AM – 1:30 PM
ADT
(223) A simulation-based approach to assess the potential impact of unmeasured confounding on study validity at the design stage of non-interventional studies
Favorite
8:00 AM – 1:30 PM
ADT
(224) Validity of ICD-10 Algorithms for Ischemic and Hemorrhagic Stroke in US Medicare Older Adults
Favorite
8:00 AM – 1:30 PM
ADT
(225) A statistical test for differential sensitivity of study outcome
Favorite
8:00 AM – 1:30 PM
ADT
(226) Risk of Type 2 Diabetes Mellitus and Hyperlipidemia in Patients With Chronic Myeloid Leukemia Initiating Tyrosine Kinase Inhibitors: A Nationwide Cohort Study
Favorite
8:00 AM – 1:30 PM
ADT
(227) Risk of Cardiovascular Events with Cyclin-Dependent Kinases 4 and 6 (CDK 4/6) Inhibitors among Patients with Metastatic Breast Cancer: A Systematic Review and Network Meta-Analysis
Favorite
8:00 AM – 1:30 PM
ADT
(228) Validity of a Claims-Based Algorithm to Identify Lactic Acidosis in US Medicare
Favorite
8:00 AM – 1:30 PM
ADT
(229) Validity of Claims-Based Algorithm to Identify Venous Thromboembolism in Japan
Favorite
8:00 AM – 1:30 PM
ADT
(230) Methodological approach for estimating the prevalence of rare cancers in DARWIN EU®
Favorite
8:00 AM – 1:30 PM
ADT
(231) Evidence Supporting Product Withdrawals for Safety Reasons in Europe: Shift of the Trend Over Time
Favorite
8:00 AM – 1:30 PM
ADT
(232) Understanding Data Source Characteristics Triggering Heterogeneity When Pooling RWD Sources in Pharmacoepidemiological Studies
Favorite
8:00 AM – 1:30 PM
ADT
(233) Real-World Incidence of Selected Clinical Events in Patients Diagnosed with Myelofibrosis
Favorite
8:00 AM – 1:30 PM
ADT
(234) An iterative phenotype development and evaluation process with medical specialist input: the experience defining progressive multifocal leukoencephalopathy
Favorite
8:00 AM – 1:30 PM
ADT
(235) Statin use and sensorineural hearing loss in patients with type 2 diabetes: Evidence from a population-based case-control study
Favorite
8:00 AM – 1:30 PM
ADT
(236) Risk factors associated with the incidence of Tyrosine kinase inhibitors-induced cardiac toxicity in cancer patients: a population-based case-control study
Favorite
8:00 AM – 1:30 PM
ADT
(237) Polypharmacy and Hyperpolypharmacy among Patients with Chronic Kidney Disease: Prevalence, Geographical Difference, and Associated Factors
Favorite
8:00 AM – 1:30 PM
ADT
(238) Real-world Effectiveness and Safety of Multiple Myeloma Treatments Based on Thalidomide and Bortezomib: a Retrospective Cohort Study from 2009 to 2020 in a Brazilian Metropolis
Favorite
8:00 AM – 1:30 PM
ADT
(239) Effect of Statin Use for the Primary Prevention of Cardiovascular Disease Among Older Adults: An Observational Analysis Emulating a Target Trial
Favorite
8:00 AM – 1:30 PM
ADT
(240) Bridging clinical trial life expectancy (LE) inclusion criterion in the real-world (RW) setting: targeted literature review results for modeling feasibility in relapsed and refractory multiple myeloma (RRMM) patients
Favorite
8:00 AM – 1:30 PM
ADT
(241) Assessment of Chemotherapy-Induced Nausea and Vomiting strategies in a resource-constraint setting
Favorite
8:00 AM – 1:30 PM
ADT
(242) Using Real World Data to Inform Clinical Trial Design
Favorite
8:00 AM – 1:30 PM
ADT
(243) Prescription trends of PCSK9 inhibitors in Hong Kong
Favorite
8:00 AM – 1:30 PM
ADT
(244) A comparative safety study of generic alendronate tablet using claims database
Favorite
8:00 AM – 1:30 PM
ADT
(245) Percutaneous Transluminal Septal Myocardial Ablation and Common Procedural Complications before and after the approval of Ablysinol
Favorite
8:00 AM – 1:30 PM
ADT
(246) Development and Validation of Algorithms to Identify Endometrial Carcinoma Using ICD-9 and ICD-10 Codes in a US Healthcare Claims Database
Favorite
8:00 AM – 1:30 PM
ADT
(247) Post-authorisation safety study (PASS) assessing the risk of liver, renal, genitourinary, and diabetic ketoacidosis outcomes among users of empagliflozin versus DPP-4 inhibitors in patients with type 2 diabetes mellitus (T2D)
Favorite
8:00 AM – 1:30 PM
ADT
(248) Application of Machine Learning methods for Prediction of Tyrosine kinase inhibitor-induced hepatotoxicity in Cancer Patients
Favorite
8:00 AM – 1:30 PM
ADT
(249) Validation of Diagnoses of Hepatic Disorders in Users of Systemic Antifungal Medication in Sweden
Favorite
8:00 AM – 1:30 PM
ADT
(250) The risk of psychiatric hospitalization with medical cannabis: self-controlled case series study
Favorite
8:00 AM – 1:30 PM
ADT
(251) Assessment of fluoroquinolone related QT-interval prolonging drug interactions encountered when treating uncomplicated urinary tract infections in women residing in long-term care
Favorite
8:00 AM – 1:30 PM
ADT
(252) Effect of Drug-Drug Interaction Between Tamoxifen and CYP2D6-inhibiting Antidepressants on Cancer Recurrence and Mortality of Women with Breast Cancer: a Systematic Review
Favorite
8:00 AM – 1:30 PM
ADT
(254) Opioid overdose risk after oxycodone initiation during CYP3A4-inhibiting vs non-inhibiting calcium channel blocker therapy
Favorite
8:00 AM – 1:30 PM
ADT
(255) Risk of Severe Uterine Bleeding of Oral Anticoagulants use in Postmenopausal Women Aged 55 Years or Older: An Application of the U.S. Sentinel Routine Querying Tools to the Taiwan Sentinel Data Model
Favorite
8:00 AM – 1:30 PM
ADT
(256) Lithium Toxicity Following Co-prescription of Lithium and Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin II Receptor Blockers (ARBs)
Favorite
8:00 AM – 1:30 PM
ADT
(257) The risk of fatal opioid overdose associated with the concurrent use of opioid analgesics and psychotropic medicines: a retrospective population-based cohort study
Favorite
8:00 AM – 1:30 PM
ADT
(258) The Association between Recently Elevated Anticholinergic Burden and the Risk of Delirium: a case-cross-over study
Favorite
8:00 AM – 1:30 PM
ADT
(259) Effectiveness of the influenza vaccine among Korean adult populations from 2015/16 to 2018/19: A Nationwide Population-based Cohort Study
Favorite
8:00 AM – 1:30 PM
ADT
(260) Preliminary Findings from a Non-Interventional Post-Authorization Safety Study (PASS) for Active Safety Surveillance of Comirnaty Vaccine Recipients in the EU
Favorite
8:00 AM – 1:30 PM
ADT
(261) Low Antibody Titers Demonstrate Significantly Increased Risk of SARS-CoV-2 Infection in a Highly Vaccinated Population from the National Basketball Association
Favorite
8:00 AM – 1:30 PM
ADT
(262) Signal detection, refinement, & evaluation of cerebral venous sinus thrombosis following Spikevax administration in a US active surveillance system
Favorite
8:00 AM – 1:30 PM
ADT
(263) Post-Authorization Safety Study: Cohort Event Monitoring for CYD-TDV Dengue Vaccine (DNG15)
Favorite
8:00 AM – 1:30 PM
ADT
(264) Are maternal vaccines effective and safe in mothers and infants? A systematic review and meta-analysis of randomized controlled trials
Favorite
8:00 AM – 1:30 PM
ADT
(266) Changes in vaccination patterns for infants after the introduction of DTaP-IPV/Hib combination vaccines
Favorite
8:00 AM – 1:30 PM
ADT
(267) Endemic Human Coronaviruses: An Opportunity for Vaccination
Favorite
8:00 AM – 1:30 PM
ADT
(268) Exploring determinants of vaccine hesitancy among pregnant women: a behavioral analysis using Theoretical Domains Framework
Favorite
8:00 AM – 1:30 PM
ADT
(269) Association between simultaneous vaccination with live and inactivated vaccines and risk of hospitalization for non-vaccine-targeted infections
Favorite
8:00 AM – 1:30 PM
ADT
(270) Association between Enterovirus 71 (EV71) Vaccination and Risk of Henoch‑Schönlein purpura: a Population-based Near Real-Time Surveillance Study
Favorite
8:00 AM – 1:30 PM
ADT
(271) Utilization of a Hybrid Data Environment Linking Registry, Claims and EHR to Identify Myocarditis Patients
Favorite
8:00 AM – 1:30 PM
ADT
(272) Estimation of association between Vaccine Associated Paralytic Poliomyelitis and Polio Vaccine using VAERS Database: A 34 Year Data Mining
Favorite
8:00 AM – 1:30 PM
ADT
(273) Validation of a Claims-based Algorithm for Myocarditis/Pericarditis in Pediatric Patients
Favorite
8:00 AM – 1:30 PM
ADT
(274) The immunogenicity and Safety of the BBIBP-CorV (Sinopharm) Inactivated SARS-COV-2 Vaccine: A Prospective Observational Study in Indonesia
Favorite
8:00 AM – 1:30 PM
ADT
(275) Post-marketing surveillance for the safety of the 9-valent human papillomavirus vaccine in China: a retrospective real-world study
Favorite
8:00 AM – 1:30 PM
ADT
(276) Healthcare Utilization Trends for RSV, Influenza, and Pneumonia among Children and Older Adults in 2020-2022
Favorite
8:00 AM – 1:30 PM
ADT
(277) RSV Outcomes Study Extension (ROSE): Epidemiological and Operational Considerations for an Observational Study Linking Real-World Data through Tokenization to the mRNA-1345 RSV Vaccine Phase 3 Clinical Trial Data in Adults
Favorite
8:00 AM – 1:30 PM
ADT
(278) Adapting clinical endpoints to a real-world setting in vaccine effectiveness and safety studies
Favorite
8:00 AM – 1:30 PM
ADT
(279) Response rate of participant centered active surveillance of adverse event following immunization: A systematic review and Meta-analysis
Favorite
8:00 AM – 1:30 PM
ADT
(281) Human Papilloma Virus vaccine: India has Knowledge & Intention-action gap?
Favorite
8:00 AM – 1:30 PM
ADT
(282) Representation of study scripts to improve transparency and efficiency in multidatabase distributed vaccine studies
Favorite
8:00 AM – 1:30 PM
ADT
(283) The Impact of Guideline and Formulary Changes on Prescribing of Oral Vancomycin and Fidaxomicin for Treatment of Clostridioides Difficile Infections in Ontario Canada
Favorite
8:00 AM – 1:30 PM
ADT
(284) Rural Residence is Associated with Limited Guideline Concordant Cholesterol Management in Newly Treated Type 2 Diabetes
Favorite
8:00 AM – 1:30 PM
ADT
(285) Auditing Antibiotic Dispensing Practices in Community Pharmacies in 5 EU Countries
Favorite
8:00 AM – 1:30 PM
ADT
(286) Explaining Regional Variations in Outpatient Antibiotic Prescribing: A Small Area Analysis Including Over 16 Million Persons in Germany
Favorite
8:00 AM – 1:30 PM
ADT
(287) A Cross-Sectional Evaluation of Anticoagulation Control in Patients Receiving Warfarin in Nine African Countries
Favorite
8:00 AM – 1:30 PM
ADT
(288) Do’s and Don’ts for the European Community Pharmacist When Dispensing Antibiotics: A Delphi Study
Favorite
8:00 AM – 1:30 PM
ADT
(289) Survival benefit of direct-acting antiviral agents on HCV-related HCC
Favorite
8:00 AM – 1:30 PM
ADT
(290) Helicobacter Pylori Eradication Treatment and Subsequent Colorectal Cancer (CRC) Risk
Favorite
8:00 AM – 1:30 PM
ADT
(291) The Real-Life Effectiveness of Antiviral Therapy in Hepatocellular Carcinoma Patients with Low HBV-DNA Levels After Hepatectomy: A Retrospective Cohort Study in Taiwan
Favorite
8:00 AM – 1:30 PM
ADT
(292) Infection and Risk of Breast Cancer Recurrence: A Danish Nationwide Case-Control Study
Favorite
8:00 AM – 1:30 PM
ADT
(293) Association Between β-lactam Allergy Documentation and Outpatient Antibiotic Prescribing in Primary Healthcare Facilities in China
Favorite
8:00 AM – 1:30 PM
ADT
(294) Drug use evaluation comparing sedative-hypnotic drug use in hospitalized inpatients in two Canadian community hospitals
Favorite
8:00 AM – 1:30 PM
ADT
(296) A Post Authorization Safety Study of Long-Term Voriconazole Use in Sweden: A Population Based Cohort Study
Favorite
8:00 AM – 1:30 PM
ADT
(297) Frequency of adverse events of antiretroviral therapy in women living with HIV/AIDS: a systematic review and meta-analysis
Favorite
8:00 AM – 1:30 PM
ADT
(298) Effectiveness of Monovalent COVID-19 Booster/Additional Vaccine Doses in the United States
Favorite
8:00 AM – 1:30 PM
ADT
(299) Effectiveness of a Fourth Dose of mRNA-1273 Vaccine Against COVID-19 Among Older Adults in the United States
Favorite
8:00 AM – 1:30 PM
ADT
(300) Effectiveness of mRNA-1273 Bivalent (original and omicron BA.4/BA.5) COVID-19 Vaccine Against Hospitalizations for COVID-19, Medically Attended SARS-CoV-2 Infections, and COVID-19 Hospital Deaths in the United States
Favorite
8:00 AM – 1:30 PM
ADT
(301) Methodological development of an enhanced safety surveillance for the Janssen COVID-19 vaccine (JCOVDEN) through rapid cycle analysis of US administrative claims data
Favorite
8:00 AM – 1:30 PM
ADT
(302) Changing Profiles of Populations Receiving COVID-19 Vaccines - Differing Underlying Risks for Adverse Events
Favorite
8:00 AM – 1:30 PM
ADT
(303) Cardiovascular, neurological, and immunological adverse events associated with 23-valent pneumococcal polysaccharide vaccine among older adults: a nationwide self-controlled risk interval study
Favorite
8:00 AM – 1:30 PM
ADT
(304) Effectiveness of COVID-19 Vaccine in SARs-CoV-2 Infected Patients with Chronic Kidney Disease
Favorite
8:00 AM – 1:30 PM
ADT
(305) Risk of gestational outcomes and adverse events following immunization with influenza vaccine in pregnant women
Favorite
8:00 AM – 1:30 PM
ADT
(C01) Agreement of COVID-19 Incidence Between the Authoritative Data and Real-World Evidence in England
Favorite
8:00 AM – 1:30 PM
ADT
(C02) Anonymized tokenization technology to link real world data and assess the potential for exposure misclassification for pharmacoepidemiology research
Favorite
8:00 AM – 1:30 PM
ADT
(C03) Contemporary pharmacoepidemiology practice for real world data source identification and feasibility assessment – Results from an ISPE-sponsored online survey
Favorite
8:00 AM – 1:30 PM
ADT
(C04) European Rare Disease Registries: A Collaborative Effort to Assess the Quality and Suitability of Registries to Describe the Natural History of Disease and Treatment Landscape of Spinal Muscular Atrophy
Favorite
8:00 AM – 1:30 PM
ADT
(C05) Phased Target Trial Design and Meta-Analysis in a Head-to-Head Treatment Comparison
Favorite
8:00 AM – 1:30 PM
ADT
(C06) The risk of incident dementia and Alzheimer’s disease after the use of centrally-acting versus non-centrally acting angiotensin-converting enzyme inhibitors: a target trial emulation study
Favorite
8:00 AM – 1:30 PM
ADT
(C08) Using Historical RCT Controls to Contextualize Necessity of Unblinding of Serious Adverse Events and Adverse Events of Special Interest – Conceptual Framework and Database Development
Favorite
8:00 AM – 1:30 PM
ADT
(C09) Diabetes medication use in digital hospitals in China: a cross-sectional descriptive study
Favorite
8:00 AM – 1:30 PM
ADT
(C10) Early identification of patients at risk for Type-2 diabetes using machine learning models
Favorite
8:00 AM – 1:30 PM
ADT
(C11) Effect of Mobile Applications on the Spontaneous Reporting of Adverse Drug Reactions: A Systematic Review and Individual Patient Data Meta-Analysis
Favorite
8:00 AM – 1:30 PM
ADT
(C12) Identification of Treatment-Resistant Major Depressive Disorder using a Machine Learning Algorithm
Favorite
8:00 AM – 1:30 PM
ADT
(C13) Machine learning (ML) model for prediction of pneumonitis using real-world data (RWD) on immune checkpoint inhibitor (ICI)-treated advanced non-small cell lung cancer (aNSCLC)
Favorite
8:00 AM – 1:30 PM
ADT
(C14) Switching codeine to a prescription-only drug successfully reduced public engagement: An exploratory analysis using Google Trends
Favorite
8:00 AM – 1:30 PM
ADT
(C15) Use of A Wearable Activity Tracker to Assess Differences in REM Sleep Duration Among Adolescents With and Without Depression
Favorite
8:00 AM – 1:30 PM
ADT
(C16) Wearables and digital tools for infectious disease: Overview of existing digital contact tracing systems
Favorite
8:00 AM – 1:30 PM
ADT
(C17) Do Enrollment Gaps Matter? A Real-World Study of Administrative Health Claims Gaps Using the Sentinel Common Data Model
Favorite
8:00 AM – 1:30 PM
ADT
(C18) Drug Utilization Patterns among Patients Hospitalized with COVID-19 in the United States, January 2021– February 2022
Favorite
8:00 AM – 1:30 PM
ADT
(C19) Opioid and benzodiazepine prescribing patterns for noncancer pain in primary care practices in Nova Scotia, Canada from 2011-2018
Favorite
8:00 AM – 1:30 PM
ADT
(C20) Patient characteristics and treatment patterns for migraine patients initiating erenumab in Denmark and Sweden
Favorite
8:00 AM – 1:30 PM
ADT
(C21) Paxlovid or Molnupiravir Post-Treatment Medication Use Evaluation of Rebound COVID-19
Favorite
8:00 AM – 1:30 PM
ADT
(C22) Plaque Psoriasis in the Real-World Setting: Disease Activity and Initiation of Advanced Therapy
Favorite
8:00 AM – 1:30 PM
ADT
(C23) Racial-Ethnic Differences in ADHD Diagnosis and Pharmacotherapy Among Adolescents and Emerging Adults in a US Commercial Healthcare Claims Database
Favorite
8:00 AM – 1:30 PM
ADT
(C24) Temporal Trends in Use of Old and New Intravenous Iron Formulations among US Medicare Beneficiaries, 2008-2019
Favorite
8:00 AM – 1:30 PM
ADT
(C25) A data mining approach for the discovery of potentially high- and low-risk high-order drug combinations from real world data
Favorite
8:00 AM – 1:30 PM
ADT
(C26) A Review of Existing Clinical Guideline Recommendations for Contraceptive Selection in Women with Epilepsy with a Focus on Drug-Drug Interactions
Favorite
8:00 AM – 1:30 PM
ADT
(C27) Concomitant use of selective serotonin reuptake inhibitors with oral anticoagulants and the risk of major bleeding in patients with atrial fibrillation
Favorite
8:00 AM – 1:30 PM
ADT
(C28) Evaluation of QT Prolongation Associated with Haloperidol Using KIDS-KAERS Database, 2016-2020
Favorite
8:00 AM – 1:30 PM
ADT
(C29) Network Analysis of Anticholinergic Medication Use in a Cohort of People Aging with HIV: Identification of Anticholinergic Medication Drivers of Physical Frailty States
Favorite
8:00 AM – 1:30 PM
ADT
(C30) Review of Case Reports and Analysis of VigiBase Data to Identify Potential Cannabis Natural-Product Drug Interactions
Favorite
8:00 AM – 1:30 PM
ADT
(C31) The effect of isoniazid use for tuberculosis prevention on pregnancy incidence among women living with HIV on antiretroviral treatment and progestin-based hormonal contraception
Favorite
8:00 AM – 1:30 PM
ADT
(C32) The Interaction Between Gliclazide and Omeprazole via CYP2C19 and the Risk of Hypoglycaemia: A Case-Crossover Study using Primary Care Data from the UK
Favorite
8:00 AM – 1:30 PM
ADT
(C33) Effects of PM2.5 Exposure and Anticoagulant Use on Bleeding Events in a High-Risk Medicare Cohort: Evidence of Drug - Air Pollution Interaction
Favorite
8:00 AM – 1:30 PM
ADT
(C34) Environmental burden and utilization of analgesics around Lake Mälaren, Sweden’s largest drinking water source
Favorite
8:00 AM – 1:30 PM
ADT
(C35) Geographical visualization of urinary Escherichia coli resistance in the Illawarra region, Australia
Favorite
8:00 AM – 1:30 PM
ADT
(C36) Human health risk assessment and meta-analysis of arsenic-contaminated drinking water in endemic regions of India
Favorite
8:00 AM – 1:30 PM
ADT
(C37) Changes in Comorbidity / Multimorbidity within 5 Years, Post-Recruitment into the UK Biobank
Favorite
8:00 AM – 1:30 PM
ADT
(C38) Effects of Genetic Polymorphism and Drug-Drug Interaction on Outcomes of Clopidogrel Treatment
Favorite
8:00 AM – 1:30 PM
ADT
(C39) Genetic polymorphism and risk of anti-tuberculosis drug-induced liver injury (ATDILI): a systematic review and meta-analysis
Favorite
8:00 AM – 1:30 PM
ADT
(C40) Implementing Mendelian randomization to assess foetal risk from intrauterine prescriptive drugs for the treatment of glycaemic conditions, hypertension and thyroidism in pregnancy
Favorite
8:00 AM – 1:30 PM
ADT
(C41) Individual and Interactive Effects of Three Common Polymorphisms in APOA1 Gene and Obesity on Lipid-lowering Efficacy of statin
Favorite
8:00 AM – 1:30 PM
ADT
(C42) Pharmacogenetic Testing in Switzerland: a Descriptive Study Using Swiss Claims Data
Favorite
8:00 AM – 1:30 PM
ADT
(C43) Sclerostin inhibition and cardiovascular risk: triangulating the evidence using Mendelian randomisation methods
Favorite
8:00 AM – 1:30 PM
ADT
(C44) Utilization of Drugs with Pharmacogenetic Dosing Recommendations in Children in Switzerland: a Descriptive Study Using Swiss Claims Data
Favorite
8:00 AM – 1:30 PM
ADT
(C45) Comparative safety of adding SNRIs versus NSAIDs to short-acting opioid for non-malignant pain in nursing homes
Favorite
8:00 AM – 1:30 PM
ADT
(C46) Evidence-based data for the use of newly approved medications in older adults: a descriptive analysis from clinical trials to product monographs
Favorite
8:00 AM – 1:30 PM
ADT
(C47) Heterogeneous Treatment Effects of Metformin on the Risk of Dementia in People with Type 2 Diabetes: A Longitudinal Observational Study
Favorite
8:00 AM – 1:30 PM
ADT
(C48) Incidence and prevalence of Parkinson’s disease and utilisation of antiparkinson treatments: a population-based cohort study
Favorite
8:00 AM – 1:30 PM
ADT
(C49) Potential inappropriate medication use among older patients with Parkinson’s disease: A cross sectional analysis of a national health insurance database in China
Favorite
8:00 AM – 1:30 PM
ADT
(C50) Redefining Polypharmacy in Older People Taking into Account Longitudinality: A Joint Latent Class Analysis
Favorite
8:00 AM – 1:30 PM
ADT
(C51) Statins discontinuation near the end of life: a retrospective cohort study using electronic health records
Favorite
8:00 AM – 1:30 PM
ADT
(C52) Validating Medicare claims-based algorithms for deprescribing of benzodiazepines using a novel linkage with electronic health records data
Favorite
Back to Top
